The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.
Daver NG, Vyas P, Huls GA, Döhner H, Maury S, Novak J, Papayannidis C, Martinez Chamorro C, Montesinos P, Niroula R, Fenaux P, Esteve J, Wu SJ, De Voeght A, Mayer J, Valk PJM, Johnson L, Dong M, Liu K, Kuwahara SB, Caldwell K, Guru Murthy GS.
Daver NG, et al. Among authors: mayer j.
Blood. 2025 Apr 15:blood.2024027506. doi: 10.1182/blood.2024027506. Online ahead of print.
Blood. 2025.
PMID: 40233321